APTOF
Price
$3.00
Change
+$0.40 (+15.38%)
Updated
Apr 4 closing price
Capitalization
8.62M
SLNO
Price
$69.74
Change
+$2.26 (+3.35%)
Updated
Apr 7, 04:59 PM (EDT)
Capitalization
3.09B
36 days until earnings call
Ad is loading...

APTOF vs SLNO

Header iconAPTOF vs SLNO Comparison
Open Charts APTOF vs SLNOBanner chart's image
Aptose Biosciences
Price$3.00
Change+$0.40 (+15.38%)
Volume$22.82K
Capitalization8.62M
Soleno Therapeutics
Price$69.74
Change+$2.26 (+3.35%)
Volume$34.92K
Capitalization3.09B
APTOF vs SLNO Comparison Chart
Loading...
APTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APTOF vs. SLNO commentary
Apr 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APTOF is a StrongBuy and SLNO is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 08, 2025
Stock price -- (APTOF: $3.00 vs. SLNO: $67.48)
Brand notoriety: APTOF and SLNO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APTOF: 0% vs. SLNO: 108%
Market capitalization -- APTOF: $8.62M vs. SLNO: $3.09B
APTOF [@Biotechnology] is valued at $8.62M. SLNO’s [@Biotechnology] market capitalization is $3.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $283.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APTOF’s FA Score shows that 0 FA rating(s) are green whileSLNO’s FA Score has 0 green FA rating(s).

  • APTOF’s FA Score: 0 green, 5 red.
  • SLNO’s FA Score: 0 green, 5 red.
According to our system of comparison, SLNO is a better buy in the long-term than APTOF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APTOF’s TA Score shows that 6 TA indicator(s) are bullish while SLNO’s TA Score has 6 bullish TA indicator(s).

  • APTOF’s TA Score: 6 bullish, 3 bearish.
  • SLNO’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, APTOF is a better buy in the short-term than SLNO.

Price Growth

APTOF (@Biotechnology) experienced а -9.64% price change this week, while SLNO (@Biotechnology) price change was -6.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.36%. For the same industry, the average monthly price growth was -17.88%, and the average quarterly price growth was -17.48%.

Reported Earning Dates

SLNO is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-9.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLNO($3.09B) has a higher market cap than APTOF($8.62M). APTOF YTD gains are higher at: 1231.558 vs. SLNO (50.122). APTOF has higher annual earnings (EBITDA): -24.82M vs. SLNO (-173.63M). SLNO has more cash in the bank: 291M vs. APTOF (3.32M). APTOF has less debt than SLNO: APTOF (10.7M) vs SLNO (52.8M). APTOF (0) and SLNO (0) have equivalent revenues.
APTOFSLNOAPTOF / SLNO
Capitalization8.62M3.09B0%
EBITDA-24.82M-173.63M14%
Gain YTD1231.55850.1222,457%
P/E RatioN/AN/A-
Revenue00-
Total Cash3.32M291M1%
Total Debt10.7M52.8M20%
FUNDAMENTALS RATINGS
APTOF vs SLNO: Fundamental Ratings
APTOF
SLNO
OUTLOOK RATING
1..100
1250
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10056
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
3435
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APTOF's Valuation (90) in the Biotechnology industry is in the same range as SLNO (100) in the Medical Specialties industry. This means that APTOF’s stock grew similarly to SLNO’s over the last 12 months.

SLNO's Profit vs Risk Rating (56) in the Medical Specialties industry is somewhat better than the same rating for APTOF (100) in the Biotechnology industry. This means that SLNO’s stock grew somewhat faster than APTOF’s over the last 12 months.

SLNO's SMR Rating (95) in the Medical Specialties industry is in the same range as APTOF (99) in the Biotechnology industry. This means that SLNO’s stock grew similarly to APTOF’s over the last 12 months.

APTOF's Price Growth Rating (34) in the Biotechnology industry is in the same range as SLNO (35) in the Medical Specialties industry. This means that APTOF’s stock grew similarly to SLNO’s over the last 12 months.

APTOF's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SLNO (100) in the Medical Specialties industry. This means that APTOF’s stock grew similarly to SLNO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APTOFSLNO
RSI
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
89%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
89%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
65%
Bullish Trend 4 days ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 11 days ago
86%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
72%
Bearish Trend 4 days ago
82%
Aroon
ODDS (%)
Bullish Trend 4 days ago
67%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
APTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRWRX19.16-1.15
-5.66%
MFS Blended Research Growth Eq R1
LSIFX114.14-7.07
-5.83%
ClearBridge Growth IS
ECERX16.77-1.07
-6.00%
Eaton Vance Stock C
NPFCX51.68-3.36
-6.10%
American Funds New Perspective C
CSHZX11.21-1.08
-8.79%
NYLI Cushing® MLP Premier Class I

APTOF and

Correlation & Price change

A.I.dvisor tells us that APTOF and BDTX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APTOF and BDTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APTOF
1D Price
Change %
APTOF100%
+15.38%
BDTX - APTOF
30%
Poorly correlated
-7.28%
LOGC - APTOF
28%
Poorly correlated
-6.17%
MDGL - APTOF
28%
Poorly correlated
-3.89%
SLNO - APTOF
28%
Poorly correlated
-6.49%
HUMA - APTOF
27%
Poorly correlated
-6.90%
More

SLNO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLNO has been loosely correlated with BRNS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SLNO jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNO
1D Price
Change %
SLNO100%
-6.49%
BRNS - SLNO
56%
Loosely correlated
-10.26%
KANT - SLNO
45%
Loosely correlated
N/A
NKTX - SLNO
43%
Loosely correlated
-4.40%
ACLX - SLNO
40%
Loosely correlated
-6.17%
SYRE - SLNO
39%
Loosely correlated
-8.58%
More